ADHD Innovation & Patent Landscape (2024-2026)

Overview

1. Drug Delivery & Formulation (Most Active Patent Territory)

What's already patented (prior art)

• Pulsatile/osmotic extended-release systems for amphetamine salts and methylphenidate (multiple assignees, US/WO/CN/DE jurisdictions)
• Night-administration delayed-release formulations designed for morning symptom control on waking
• 3D-printed fixed-dose combinations - Triastek is a key assignee; this allows precise multi-compartment drug release profiles in a single pill
• Non-stimulant combinations: Atomoxetine, guanfacine, clonidine as combination partners rather than standalone drugs

Emerging frontiers with open IP

• mGluR (metabotropic glutamate receptor) modulators - Fasoracetam (NFC-1) already showed efficacy in ADHD patients with mGluR mutations; genetically stratified prescribing is a major gap
• KDM1A (LSD1) epigenetic targets - Epigenetic mechanisms in ADHD are early-stage; minimal patent filings exist
• Epigenetic diagnostic biomarkers - University of Teramo has a diagnostic patent around methylation of the dopamine transporter gene SLC6A3; pairing this with a companion therapeutic is an open opportunity following the oncology companion diagnostic model

Patent opportunity: A "diagnose-then-match" platform combining an SLC6A3 methylation test with a mechanism-specific drug is well-grounded in research and sparsely patented in CNS.

2. Neurostimulation & Neurofeedback Devices

What's cleared/patented

• EndeavorRx (AKL-T01, Akili Interactive) - FDA-cleared video game-based digital therapeutic for pediatric ADHD attention; the key prior art in gamified cognitive training
• Lumosity Rx - FDA cleared for adult ADHD (ages 22-55); app-based attention and working memory training
• External Trigeminal Nerve Stimulation (eTNS) - The Monarch eTNS system (Neuropace/NeuroSigma) targets the trigeminal nerve; FDA cleared for pediatric ADHD
• tDCS (transcranial direct current stimulation) wearables - Several research and commercial filings exist

What the research says is still underexplored

• A 2025 JAMA Psychiatry meta-analysis (PMID: 39661381) on neurofeedback for ADHD found that, while theta/beta ratio training shows effects, protocol standardization is lacking - this gap is where IP can be built
• Combining tDCS + neurofeedback in a closed-loop system: A 2025 Frontiers in Systems Neuroscience paper specifically identifies this combo as a "feedback-enhanced neuromodulation loop" with synergistic effects - minimal commercial patents exist for this dual-modal approach
• Wearables disguised as everyday objects (hats, glasses frames) - A 2025 adherence study from Texas A&M noted children prefer therapeutic devices that look like clothing accessories; the form factor patent space here is sparse

Patent opportunity: A closed-loop, adaptive tDCS + EEG neurofeedback wearable (hat/headband form factor) that adjusts stimulation intensity in real time based on EEG feedback - supported by the Frontiers 2025 paper and 2025 JAMA meta-analysis data.

3. Digital Therapeutics & AI

What's approved/active

• Game-based cognitive training (EndeavorRx, Lumosity Rx) - attention, working memory, inhibitory control
• AI writing assistants for ADHD students (adaptive difficulty, real-time grammar/organization feedback)
• Telehealth platforms with integrated symptom tracking

What research shows is needed

• A 2025 systematic review of systematic reviews (PMID: 40264083, BMC Psychiatry) on digital ADHD interventions found that evidence quality is low-moderate and that long-term outcome tracking is a key gap
• Explainable AI (XAI) for teachers - AI that explains why it's flagging a student's attention state, not just that it has; bias-audited for neurodivergent populations
• Parent-facing mobile training - A 2025 RCT (PMID: 40576800) confirmed efficacy of mobile parent management training, but adherence features (personalized scheduling, micro-coaching) remain underpatented
• AI-driven pharmacogenomic prescribing for ADHD - pairing genetic markers (e.g., CYP2D6, DRD4 variants) with stimulant vs. non-stimulant recommendations at the point of prescribing

Patent opportunity: An AI-powered ADHD care navigator that integrates pharmacogenomic data, real-time symptom tracking (via passive sensing on smartphone or wearable), and treatment recommendation optimization - with a transparent, explainable output for clinicians and parents.

4. Education & Assistive Technology

Active space

• Adaptive learning platforms adjusting task difficulty based on inferred attention state
• AI writing assistants (Sharma & Solis 2024: 60-student RCT showed improved writing speed and reduced cognitive load)

Research gaps / patent-thin areas

• Classroom environmental sensing (noise, light, CO2 levels) correlated with ADHD attention states - no known issued patents linking classroom IoT data to individualized ADHD accommodations
• Emotion + focus biometric fusion for real-time teacher dashboards - combining facial action units, keystroke dynamics, and motion to infer off-task states without requiring a wearable on the child

Patent opportunity: A passive classroom attention monitoring system using computer vision + acoustic sensing that generates per-student ADHD accommodation recommendations without any on-body device.

Summary: White Space Map

Key Research Sources Supporting These Directions

1. Neurofeedback JAMA meta-analysis (2025) - PMID 39661381: confirms neurofeedback works but protocols need standardization
2. Digital ADHD interventions review of reviews (2025) - PMID 40264083: maps evidence gaps in digital tools
3. tDCS + neurofeedback combination - Frontiers in Systems Neuroscience 2025: supports closed-loop neuromodulation concept
4. EEG neurofeedback in video games - PubMed 2026: single-channel EEG + game = attention improvements (strong novelty basis)
5. PatSnap ADHD patent data: formulation IP dominates; mGluR and epigenetic mechanisms are frontier territory
6. Parent mobile training RCT - PMID 40576800 (2025): efficacy confirmed, adherence features underexplored